NewSelf Review
Best for: lowest-cost compounded GLP-1 with pharmacy quality transparency
NewSelf offers compounded semaglutide+ (with B12/Glycine, from $99.97/mo) and compounded tirzepatide+ (with B6/Glycine, from $144.49/mo). LegitScript certified. Available in 48 states + Puerto Rico. Uses 503A licensed pharmacies with third-party testing.
High confidence · Last verified 2026-04-10 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
NewSelf is one of the most affordable GLP-1 options on the market.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Semaglutide+ (best price) | compounded | $100 |
| Semaglutide+ (regular) | compounded | $135 |
| Tirzepatide+ (best price) | compounded | $144 |
| Tirzepatide+ (regular) | compounded | $225 |
✓ Pros
- •Semaglutide+ from $99.97/mo — among the lowest prices in the dataset
- •All dosages at the same price — no price escalation as dose increases
- •LegitScript certified with 503A licensed pharmacies
- •Third-party potency, sterility, and endotoxicity testing
- •48 states + Puerto Rico coverage
- •B12/B6 + Glycine enhanced formulations
- •No membership fees
✗ Cons
- •Not available in Mississippi and Louisiana
- •Compounded only — no brand-name options
- •Site also promotes AI health optimization and longevity (broader platform)
Ready to start with NewSelf?
Starting at $100/month. See current pricing and start your free consultation.
Sources & methodology
Our NewSelf review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to NewSelf
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with NewSelf?
Starting at $100/month. See current pricing and start your free consultation.